X4 Pharmaceuticals (XFOR) has issued an announcement.
X4 Pharmaceuticals has shared promising interim results from their Phase 2 clinical trial of mavorixafor in treating chronic neutropenia (CN), revealing that the drug was well tolerated and effectively increased absolute neutrophil counts. This has led to the initiation of a pivotal Phase 3 trial aimed at further evaluating mavorixafor’s safety and efficacy. The positive outcomes from the Phase 2 trial, which involved both monotherapy and combination therapy with G-CSF, are significant for patients with CN, who currently have limited treatment options.
For an in-depth examination of XFOR stock, go to TipRanks’ Stock Analysis page.
